News Oculis takes second eye disease therapy into pivotal trials Oculis is poised to start registration trials for privosegtor, its drug candidate for neuro-ophthalmic diseases, in the wake of positive phase 2 data.
News Delayed TNBC readout for Datroway delivers survival benefit AstraZeneca and Daiichi Sankyo's Datroway comes good in the delayed TROPION-Breast02 trial as a frontline triple-negative breast cancer treatment.
R&D Q3 Clinical trials round-up: July to September 2025 As the third quarter of 2025 draws to a close, the clinical research landscape has been marked by a surge of promising data and regulatory milestones.
Patients Streamlining post-trial treatment access for rare disease pa... Companies have a practical and ethical responsibility to continue treating patients when clinical trial data collection ends mid-trial.
News Data backs Vertanical's cannabis therapy for back pain A phase 3 trial of Vertanical's cannabis extract in back pain has been published, and the results bode well for marketing applications under review.
News Enhertu scores again in early breast cancer AstraZeneca and Daiichi Sankyo are eyeing regulatory filings for Enhertu in early breast cancer after a second phase 3 trial delivers.
News FDA follows experts' advice and blocks Capricor DMD therapy The FDA has dashed Capricor's hope of getting approval for its cell therapy for Duchenne muscular dystrophy, wreaking havoc with its share price.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.